Abstract
The appeal of urinary biomarkers is an obvious one. The potential to diagnose a disease earlier, direct treatment more efficiently, and assess for progression or recurrence could all be game-changing tools in our armamentarium. Indeed, PCA3 has already been FDA-approved for prostate cancer assessment and the AUA/SUO Joint Guideline on non-muscle invasive bladder cancer established an Expert Opinion that UroVysion® FISH and ImmunoCyt™ may be used to assess response to intravesical BCG and adjudicate equivocal cytology. 1 Chang S.S. Boorjian S.A. Chou R. et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. http://www.auanet.org/education/guidelines/non-muscle-invasive-bladder-cancer.cfmDate: 2016 Google Scholar Other biomarkers for both types of cancers are well into development and testing.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
